Jon Christian Bates - 01 Apr 2023 Form 4 Insider Report for Nutex Health, Inc. (NUTX)

Role
Chief Financial Officer
Signature
/s/ John C. Bates
Issuer symbol
NUTX
Transactions as of
01 Apr 2023
Net transactions value
$0
Form type
4
Filing time
10 May 2023, 16:00:08 UTC
Previous filing
21 Jul 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUTX Common Stock Options Exercise $0 +49,505 $0.000000 49,505 01 Apr 2023 Direct F1
transaction NUTX Common Stock Options Exercise $0 +20,000 +40% $0.000000 69,505 01 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUTX Restricted Stock Unit Award $0 +148,515 $0.000000 148,515 01 Apr 2023 Common Stock 148,515 Direct F1, F2
transaction NUTX Restricted Stock Unit Options Exercise $0 -49,505 -33% $0.000000 99,010 01 Apr 2023 Common Stock 49,505 Direct F1, F2
transaction NUTX Restricted Stock Unit Award $0 +20,000 $0.000000 20,000 01 Apr 2023 Common Stock 20,000 Direct F1, F3
transaction NUTX Restricted Stock Unit Options Exercise $0 -20,000 -100% $0.000000* 0 01 Apr 2023 Common Stock 20,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
F2 Pursuant to the Restricted Stock Unit Agreement by and between the issuer and Mr. Bates, dated April 1, 2023, the 148,515 RSUs granted to Mr. Bates will vest in three equal installments, with the initial 1/3 immediately vested on April 1, 2023, and the remaining RSUs vesting 1/3 each on March 1, 2024 and March 1, 2025.
F3 Represents 20,000 RSUs issued and vested on April 1, 2023.